Show results for
Refine by
Methicillin Resistant Staphylococcus Aureus Mrsa Articles & Analysis
66 news found
Methicillin-resistant Staphylococcus aureus (MRSA) is described by the National Institute for Occupational Safety and Health (NIOSH) as a potentially dangerous type of staph bacteria. Staph, which is commonly carried on the skin or in the nose of healthy people, can sometimes cause infections, but most of these ...
The Centers for Disease Control and Prevention describe Methicillin-resistant Staphylococcus aureus (MRSA) as a type of staph that can be resistant to several antibiotics. The agency warns that anyone can get a MRSA infection or carry MRSA. The risks increase for ...
Their newest production discusses World MRSA Awareness Month which takes place each October. “Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph that can be resistant to several antibiotics,” said Paul Cochrane, President of Cochrane & ...
The study was performed using two representative species of bacteria – Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative Pseudomonas aeruginosa. ...
Staphylococcus aureus is a type of bacteria that has long been recognized as a cause of disease. ...
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
XF-73 Nasal targeting peak sales potential of $1 billion in its major target markets Phase 3 patient recruitment could start in 2024 subject to completing an XF-73 Nasal partnering deal in 2023 XF-73 Nasal is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical staphylococcal infections, such as ...
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane. The patent, titled “Bismuth-thiol compositions and methods for treating wounds,” adds to Microbion’s growing portfolio of intellectual property on the ...
Canadian life sciences company, Ondine Biomedical Inc. (LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance Congress, in Maryland, USA on the effectiveness of its photodisinfection technology against the group of highly infectious and antibiotic-resistant bacteria known as ESKAPE pathogens.[i] ESKAPE pathogens are the most virulent and dangerous pathogens ...
The Centers for Disease Control and Prevention (CDC) established the Antibiotic Resistance Laboratory Network (AR Lab Network) in all 50 states back in 2016. It was designed to help detect new forms of drug resistance from germs like bacteria and fungi that develop the ability to defeat the drugs that were designed to kill them. Drug resistance has become a growing concern, especially in ...
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by ...
Most of these skin infections are minor. But, with methicillin-resistant Staphylococcus aureus (MRSA), a strain of staph that is resistant to a commonly prescribed antibiotic known as methicillin and is often resistant to other antibiotics, the infections can be ...
Methicillin-resistant Staphylococcus aureus (MRSA) is described by the National Institute for Occupational Safety and Health (NIOSH) as a potentially dangerous type of staph bacteria. Staph, which is commonly carried on the skin or in the nose of healthy people, can sometimes cause infections, but most of these ...
Their newest production discusses methicillin-resistant Staphylococcus aureus (MRSA) and potential exposure risks in the work environment. “MRSA are bacteria that are resistant to an antibiotic known as methicillin, as well as other antibiotics in many ...
While much of the media’s attention has been focused on the novel coronavirus that spread across the globe this year, SARS-CoV-2 is not the only emerging threat. Just before reports of the initial outbreak of COVID-19 last year, the Centers for Disease Control and Prevention (CDC) published an update to the agency’s first Antibiotic Resistance Threats in the United States (AR Threats ...
The 2019 AR Threats Report list the CDC’s top 18 antibiotic-resistant pathogens and also includes 3 on the agency’s “Watch ...
The first recorded nosocomial outbreak of Methicillin-resistant Staphylococcus aureus (MRSA) in the United States occurred in 1968 in Boston, Massachusetts. ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph bacteria that can be found on many people’s skin or even in their nose. For those who develop a MRSA infection, it is resistant to many antibiotics which can cause serious health concerns for infected ...